Makoto Imori
Makoto Imori publishes mostly in Endocrinology, Diabetes and Metabolism, Surgery and Genetics, on topics such as Diabetes Management and Research, Diabetes Treatment and Management and Hyperglycemia and glycemic control in critically ill and hospitalized patients.
- World rank
- #6,878,996 of 7,710,434 ranked researchers
- Rank in Japan
- #295,798 of 383,136
- Works
- 18
- Citations
- 88
- Citations per work
- 4.9
What does Makoto Imori research?
Makoto Imori's work is mostly in Medicine (78%), Biochemistry, Genetics and Molecular Biology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1478.4%
- Medicine1478.4%
- Everything else315.7%
- Life Sciences15.9%
- 1Endocrinology, Diabetes and Metabolism61% of their works
- 2Surgery6% of their works
- 3Genetics6% of their works
- 4Radiology, Nuclear Medicine and Imaging4% of their works
- 5Physiology4% of their works
- 6Genetics4% of their works
Research topics
- Diabetes Management and Research
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes and associated disorders
- Diabetes Management and Education
- Pancreatic function and diabetes
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
Which keywords describe Makoto Imori's research?
The keywords of their largest research topics: Glycemic Control, Insulin Therapy, Diabetes, Type 1 Diabetes, Continuous Glucose Monitoring, Hypoglycemia, Cardiovascular Outcomes and Type 2 Diabetes.
- Genomic Aberrations
- Chronic Lymphocytic Leukemia
- Self-Management
- Genetics
- Autoimmunity
- Critical Care
- Type 2 Diabetes
- Hypoglycemia
- Type 1 Diabetes
- Insulin Therapy
- Glycemic Control
- Diabetes
- Continuous Glucose Monitoring
- Cardiovascular Outcomes
- Diabetes Mellitus
- Hyperglycemia
- Depression
- Pancreatic Islets
- ß-Cell Dysfunction
- Fc Receptors
- Therapeutic Antibodies
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Glycemic Control284 topics
- Insulin Therapy253 topics
- Diabetes142 topics
- Type 1 Diabetes142 topics
- Continuous Glucose Monitoring111 topic
- Hypoglycemia111 topic
- Cardiovascular Outcomes101 topic
- Type 2 Diabetes101 topic
- Diabetes Mellitus72 topics
- Critical Care41 topic
- Hyperglycemia41 topic
- Autoimmunity31 topic
- Depression31 topic
- Genetics31 topic
- Pancreatic Islets31 topic
- Self-Management31 topic
- ß-Cell Dysfunction31 topic
- Chronic Lymphocytic Leukemia21 topic
- Fc Receptors21 topic
- Genomic Aberrations21 topic
- Therapeutic Antibodies21 topic
Where does Makoto Imori work?
Makoto Imori's main affiliation in the publication record is Eli Lilly (Japan), Japan.
How many publications and citations does Makoto Imori have?
OpenAlex counts 18 works and 88 citations for Makoto Imori, an h-index of 5, ranking #6,878,996 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Makoto Imori. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.